Regenerative medicine has seen rapid advancements in recent years, particularly in stem cell therapies. These therapies leverage the pluripotency of stem cells, enabling them to differentiate into various cell types and repair damaged tissues, showcasing significant developmental potential.

We are collaborating with Professor Patrick C.H. Hsieh, a distinguished research fellow at the Institute of Biomedical Sciences, Academia Sinica. This project is supported by the National Science and Technology Council (NSTC) under the Precision Regenerative Medicine (PRM) program. We aim to develop and preserve allogeneic iPSC-derived endothelial cells (iPSC-ECs) to treat Critical limb ischemia (CLI). By using cell therapy to induce angiogenesis, we aim to alleviate ischemic symptoms in patients by promoting blood vessel formation in the affected areas by triggering growth factors related to vascular proliferation. Recent clinical studies have emphasized the safety and feasibility of stem cell therapy for CLI. This collaboration will integrate Academia Sinica's prior experience generating allogeneic iPSCs with our expertise in manufacturing and developing iPSC-EC products under Taiwan's Good Tissue Practice (GTP) regulations, facilitating future clinical research and academic development.